83117-41-3

Upstream product

• 65-85-0 benzoic acid 
• 57852-42-3 resiniferinol-9,13,14-ortho-phenylacetate 
• 200264-91-1 (2R,4S,5R)-5-Benzyloxy-1-[5-(tert-butyl-dimethyl-silanyloxymethyl)-furan-2-yl]-4-hydroxy-2-methyl-hept-6-en-1-one 
• 200264-94-4 Acetic acid (1R,2R,4S,5R,6S,8S)-5-benzyloxy-8-(tert-butyl-dimethyl-silanyloxymethyl)-2-methyl-11-methylene-10-oxo-12-oxa-tricyclo[6.3.1.0^1,6]dodec-4-yl ester 
• 200265-11-8 Acetic acid (1R,2R,4S,5R,6S,8S)-5-benzyloxy-8-(tert-butyl-dimethyl-silanyloxymethyl)-10-hydroxy-2-methyl-11-methylene-12-oxa-tricyclo[6.3.1.0^1,6]dodec-4-yl ester 
• 200265-10-7 Acetic acid (1R,2R,4S,5R,6S,8R)-5-benzyloxy-8-(tert-butyl-dimethyl-silanyloxymethyl)-2-methyl-11-methylene-12-oxa-tricyclo[6.3.1.0^1,6]dodec-4-yl ester 
• 200264-99-9 (2S,3aS,3bR,4R,5aS,8aR,8bS,11aR)-5a-Acetyl-3b-hydroxy-2,4-dimethyl-10-methylene-11a-trimethylsilanyloxy-dodecahydro-6,8-dioxa-indeno[5,4-e]azulene-1,7-dione 
• 200265-15-2 C₂₃H₃₄O₈Si 
• 200264-95-5 Acetic acid (1R,2R,4S,5R,6S,8S,11S)-11-allyl-5-benzyloxy-8-(tert-butyl-dimethyl-silanyloxymethyl)-2-methyl-10-oxo-12-oxa-tricyclo[6.3.1.0^1,6]dodec-4-yl ester 
• 200265-16-3 C₂₃H₃₃IO₇Si 
• 200265-00-5 (2S,3aS,3bR,4R,5aS,8aR,8bS,9R,11aR)-5a-Acetyl-3b,9-dihydroxy-2,4-dimethyl-10-methylene-11a-trimethylsilanyloxy-dodecahydro-6,8-dioxa-indeno[5,4-e]azulene-1,7-dione 
• 200264-88-6 C₄₃H₆₄O₅Si₂ 
• 200265-21-0 C₄₁H₅₄O₇Si₂ 
• 200264-96-6 Acetic acid (1R,2R,4S,5R,6S,8S,10R,11S)-11-allyl-5-benzyloxy-8-(tert-butyl-dimethyl-silanyloxymethyl)-2-methyl-10-phenylethynyl-10-trimethylsilanyloxy-12-oxa-tricyclo[6.3.1.0^1,6]dodec-4-yl ester 

Downstream Products

• 71407-32-4 C₃₉H₄₂O₁₀ 
• 57852-42-3 resiniferinol-9,13,14-ortho-phenylacetate 

Relevant academic research and scientific papers

Structure-activity relationships of the ultrapotent vanilloid resiniferatoxin (RTX): The homovanillyl moiety

Starting from ROPA (2), analogues of RTX (1a) modified on the acyl side chain were prepared and evaluated for vanilloid activity in HEK-293 cells over-expressing the human recombinant TRPV1. The ROPA motif provided an enhancement of potency sufficient to